Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaleonFRA:H6D -0.58%73 EV-to-EBIT is 16.38 as of Aug. 27, 2026, which is 13% below its 10-year median of 18.93. GuruFocus rates FRA:H6D with a GF Score™ of 73/100 and a GF Value™ of €8.57 (Fairly Valued). The stock has 4 warning signs investors should review. Among 691 Drug Manufacturers companies, Haleon ranks worse than 51.37% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Haleon's Enterprise Value is €46,299 Mil.
Haleon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,826 Mil. Therefore, Haleon's EV-to-EBIT for today is 16.38.
The historical rank and industry rank for Haleon's EV-to-EBIT or its related term are showing as below:
FRA:H6D'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.28 Med: 18.93 Max: 22.41
Current: 16.4
During the past 7 years, the highest EV-to-EBIT of Haleon was 22.41. The lowest was 14.28. And the median was 18.93.
FRA:H6D's EV-to-EBIT is ranked worse than 51.37% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.77
vs FRA:H6D: 16.40
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Haleon's Enterprise Value for the quarter that ended in Jun. 2026 was €44,085 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon EV-to-EBIT Related Terms
Haleon EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Haleon's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Haleon's EV-to-EBIT falls into.
Haleon's current Enterprise Value is €46,299 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €2,826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (FRA:H6D) has a EV-to-EBIT of 16.38 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Haleon and its competitors. This is 13% below median its historical median of 18.93. Over the past decade, Haleon's EV-to-EBIT has ranged from 14.28 to 22.41. According to the industry distribution chart, Haleon ranks #355 out of 691 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Haleon's EV-to-EBIT too high?
Haleon's current EV-to-EBIT of 16.38 is 13% below median its 10-year median of 18.93. Over the past 10 years, this metric has ranged from a low of 14.28 to a high of 22.41. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Haleon's value of 16.38 is 3.9% above this industry median. Based on the distribution chart, Haleon ranks #355 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Haleon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #355 out of 691 companies for EV-to-EBIT. This places Haleon in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Haleon's value of 16.38 is 3.9% above this benchmark. Historically, Haleon's own EV-to-EBIT has ranged from 14.28 to 22.41 over the past decade. While the company's 10-year median is 18.93 vs. the industry median of 15.77, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current EV-to-EBIT of 16.38 is 3.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current EV-to-EBIT is 16.38, which is 13% below median its own 10-year median of 18.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (FRA:H6D) is currently considered Fairly Valued. The stock's GF Value™ is €8.57, compared to a current price of €8.55 — trading 0.2% below its estimated fair value. The current EV-to-EBIT is 16.38, which is 13% below median its 10-year median of 18.93 and 3.9% above the Drug Manufacturers industry median of 15.77. Haleon's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Haleon (FRA:H6D), the current EV-to-EBIT is 16.38 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (FRA:H6D) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of €8.55 is trading 0.2% below its estimated GF Value™ of €8.57.
GuruFocus considers Haleon to be Fairly Valued.
Key valuation signals for FRA:H6D:
EV-to-EBIT: 16.38 (13% below median its 10-year median of 18.93)
GF Value™: €8.57 vs. price of €8.55 (0.2% below fair value)
Industry Position: 3.9% above the Drug Manufacturers median (#355 of 691)
No single metric tells the full story. See the FRA:H6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
73GF Score
Get the complete analysis for FRA:H6D
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H6D has been successfully added to your 
